Medtronic Plc Hits New 52-Week Low at USD 74.41

Medtronic Plc, a prominent player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 74.41 on May 11, 2026. This decline marks a significant downturn for the stock, which has experienced a 10.34% decrease over the past year, contrasting sharply with the S&P 500's performance of 30.97% during the same period. With a market capitalization of USD 113,290 million, Medtronic operates within a competitive landscape, characterized by a price-to-earnings (P/E) ratio of 20.00. The company maintains a relatively low debt-to-equity ratio of 0.43, indicating a conservative approach to leverage. Despite this, the return on equity stands at 0.00%, reflecting challenges in generating profit from shareholders' equity. Medtronic's dividend yield is currently at 3.20%, providing some income to shareholders. The stock's performance metrics reveal a mixed picture, with operating cash flow reaching a high of USD 7,146 million and a return on capital employed (ROCE) of 9.72%. However, the company has faced hurdles in long-term growth, with operating profit growing at an annual rate of 9.68% over the last five years.